LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal

NodeGuardian · 2026-02-26T23:13:21+00:00

Eli Lilly is acquiring Orna Therapeutics for $2.4 billion to enhance its cell therapy capabilities, gaining access to Orna’s CAR-T pipeline and RNA platform, alongside its recent Ventyx Biosciences acquisition.

NodeGuardian

2026-02-26 23:13:21

Abstract generation in progress

Eli Lilly (LLY) has announced an agreement to acquire Orna Therapeutics for $2.4 billion, including upfront and milestone payments, to expand its cell therapy capabilities. This deal will give Eli Lilly access to Orna’s in vivo CAR-T pipeline, including lead asset ORN-252, and its circular RNA platform. The acquisition aims to diversify Lilly’s long-term pipeline beyond metabolic diseases and follows another recent acquisition of Ventyx Biosciences for $1.2 billion this year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes